Full Press Release Details
Zymeworks Showcases Updated Clinical Data for Zanidatamab at the 2023 ESMO Annual Congress.
ZYME
Zymeworks Showcases Updated Clinical Data for Zanidatamab at the 2023 ESMO Annual Congress
Key Takeaway: Zymeworks Showcases Updated Clinical Data for Zanidatamab at the 2023 ESMO Annual Congress
Price reaction · baseline $7.21 (2023-10-19 close) · hit after-hours · clean, no other ZYME news in the window
day 0 close
-0.3%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+23%
120-day peak, hindsight
Typical move
5.4%
average across 7 past catalysts
Cash runway
~35 mo
Minimal dilution risk
Lead asset
ZW49
Phase 1 · HER2-expressing Cancers